08:00 , Jan 7, 2013 |  BC Week In Review  |  Company News

BioVectra Inc., Questcor deal

Questcor will acquire contract manufacturing company BioVectra for C$50 million ($50.3 million). BioVectra stakeholders are eligible for up to an additional C$50 million over the next three years based on BioVectra's "financial results." BioVectra is...
08:00 , Jan 15, 2007 |  BC Week In Review  |  Company News

Helix, Diagnostic Chemicals Ltd. deal

Diagnostic Chemicals' BioVectra DCL subsidiary will manufacture urease for HBP's L-DOS47 for use in clinical trials. L-DOS47, which contains multiple single-domain antibodies linked to urease, is in preclinical testing for lung cancer. Financial terms were...
08:00 , Nov 22, 2004 |  BC Week In Review  |  Company News

Lorus, BioVectra dcl deal

BioVectra will manufacture commercial-scale quantities of LOR's Virulizin macrophage activator. LOR has completed enrollment in a Phase III trial of Virulizin to treat advanced pancreatic cancer in combination with gemcitabine. Data are expected in the...